Home Combat Arthritis FDA Denies Approval for Gilead Sciences' Potential Blockbuster Arthritis Drug

FDA Denies Approval for Gilead Sciences' Potential Blockbuster Arthritis Drug

Aug 24, 2020 comments off

FDA Denies Approval for Gilead Sciences’ Potential Blockbuster Arthritis Drug

Onlookers had been expecting a thumbs up for filgotinib. Now, that won’t happen for at least another year.

Read More…

You May Also Like

Scientists develop mathematical index to distinguish healthy microbiome from diseased

Flu outbreaks may be linked to COVID-19; arthritis drug benefit seen

COVID-19 roundup: Flu may be linked with coronavirus spread, RA drug could aid recovery | Daily Sabah – Daily Sabah

Initial data from a pair of clinical trials may revive interest in arthritis drugs as COVID-19 treatments

Roche says its drugs reduce ventilator need for COVID-19 patients – Reuters UK

Flu outbreaks may be linked to COVID-19; arthritis drug benefit seen – Reuters India